deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02504359

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma

Sponsor: OHSU Knight Cancer Institute

Conditions Plasma Cell Leukemia Recurrent Plasma Cell Myeloma
Interventions Allogeneic Hematopoietic Stem Cell Transplantation Carmustine Cytarabine Etoposide Ixazomib Citrate Melphalan Methotrexate Peripheral Blood Stem Cell Transplantation Quality-of-Life Assessment Tacrolimus
Updated 10 times since 2017 Last updated: Nov 19, 2020 Started: Jul 20, 2015 Primary completion: Sep 9, 2020 Completion: Sep 9, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Plasma Cell Leukemia and Recurrent Plasma Cell Myeloma, this trial is completed. The trial is conducted by OHSU Knight Cancer Institute and has accumulated 10 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotRecruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotRecruiting~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotRecruiting~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshotActive Not Recruiting~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshotActive Not Recruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Apr 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1

▶ Show 5 earlier versions

  1. Jun 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  3. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  4. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  5. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • OHSU Knight Cancer Institute
  • Oregon Health and Science University
Data source: OHSU Knight Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations